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To test whether using disease prognosis can inform a rational approach to Active Surveillance (AS) 
for early prostate cancer 
 
Methods 
We previously developed the Cambridge Prognostics Groups (CPG), a 5-tiered model that uses PSA, 
Grade Group and stage to predict cancer survival outcomes. We applied the CPG model to a UK and 
a Swedish prostate cancer cohort to test differences in prostate cancer mortality (PCM) in men 
managed conservatively or by upfront treatment in CPG2 and 3 (which subdivides the intermediate-
risk classification) versus CPG1 (low-risk). We then applied the CPG model to a contemporary UK AS 
cohort which was optimally characterised at baseline for disease burden to identify predictors of 
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Results 
In a UK cohort (n=3659) 10-year PCM was 2.3% in CPG1, 1.5% & 3.5% in treated/untreated CPG2 and 
1.9% & 8.6% in treated/untreated CPG3. In the Swedish cohort (n=27,942): 10-year PCM was 1.0% in 
CPG1, 2.2% & 2.7% in treated/untreated CPG2 and 6.1% & 12.5% in treated/untreated CPG3. We 
then tested using progression to CPG3 as a hard endpoint in a modern surveillance cohort (n=133). 
During follow-up (median 3.5 years) only 6% (8/133) progressed to CPG3. Predictors of progression 
were a PSA density 0.15 and CPG2 at diagnosis. Progression occurred in 1%, 8% and 21% of men 
with neither factor, only one or both. In an independent Spanish AS cohort (n=143) the 
corresponding rates were 3%, 10% and 14%. 
 
Conclusion 
Using disease prognosis allows a rational approach to inclusion criteria, discontinuation triggers and 
risk-stratified management in AS.  
 
Background 
Active surveillance (AS) is now the default management for men with low-risk prostate cancer and is 
becoming increasingly popular as an option for men with intermediate-risk disease [1-2]. Designing 
criteria for inclusion, optimal surveillance regimes and triggers for discontinuation however 
continues to be problematic because of a lack of level 1 trial evidence and there is great variability in 
urological practice [3-5]. The traditional endpoints for clinical trials such as survival and metastases 
are not easily applicable to AS cohorts because of the long natural history of the disease. This is 
clearly evident from recent large trials which, while not using contemporary AS strategies, have 
shown that the majority of men diagnosed with low/intermediate-risk disease and managed 
conservatively have very few adverse events even at 10 years [6]. As a result, there are no studies 
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consensus on whether men with intermediate-risk disease should or should not be surveyed [7].  Key 
to attempting any such study is a clear idea of what the endpoint of AS should be i.e. when 
surveillance becomes unsafe and treatment becomes beneficial. While it is clear that the presence of 
high-risk features mandates treatment the critical question is whether a change from low-risk to 
intermediate-risk warrants ending surveillance.  
 
In 2016 we reported a prognostic model for newly diagnosed prostate cancer by optimising the use 
of baseline clinicopathological variables (PSA, Grade Group and clinical stage) to estimate prostate 
cancer mortality (PCM) [8-9]. The Cambridge Prognostic Group (CPG) 5-strata model has been tested 
in over 86,000 men and consistently outperformed the NICE/EAU prognostic model, regardless of 
treatment type and patient age [9]. In this model we identified a sub-stratum of intermediate-risk 
cancer with low rates of PCM (CPG2) and a group with more lethal outcomes (CPG3) [8-9]. These 
sub-groups correspond to the 2017 updated risk model revisions endorsed by the AUA/ASTRO/SIU 
guidelines and designated as “favourable” and “unfavourable intermediate-risk” respectively [10].  
Here we explored if using the CPG sub-classification of intermediate-risk could identify men with 
different benefits from immediate radical therapy versus initial surveillance. If so, this could be used 
to define which intermediate-risk men could be surveyed and specific criteria for AS discontinuation 
to inform tailored follow-up protocols. To do this we exploited different datasets (i) Longitudinal 
population datasets from UK and Sweden to compare relative mortality reductions from radical 
therapy over conservative management stratified by the CPG criteria and (ii) Contemporary AS 
cohorts from UK and Spain optimally characterised for true disease burden at the point of AS entry 












This article is protected by copyright. All rights reserved. 
Methods 
Cohorts  
Population cohorts to assess treatment vs. non-treatment related prostate cancer mortality 
The CPG model was developed and validated as previously reported [8]. For this study we reanalysed 
the PCM outcomes from men in the first 3 groups (CPG1-3) defined as – CPG1: Grade Group (GG) 1 
AND PSA < 10 ng/ml AND Stages T1–T2, CPG2: GG 2 OR PSA 10–20 ng/ml AND Stages T1–T2, CPG3: 
GG2 AND PSA 10–20 ng/ml AND Stages T1–T2, OR GG3 AND Stages T1–T2 AND PSA < 20 ng/ml 
(Table 1). These groups were studied in the following cohorts: 
UK East of England cohort: A cohort of men with primary prostate cancer (ICD10 site: C61), 
diagnosed in the East of England Cancer Network (United Kingdom) area and registered by the Public 
Health England National Cancer Registration Service – Eastern Office (NCRS(E)) was assembled as 
previously reported 8. All data were anonymized at source in the NCSR(E) before being used for 
analysis, and as a result no formal ethics review was deemed necessary. 
Prostate Cancer Data Base Sweden: The Prostate Cancer Data Base Sweden (PCBaSe) 3.0 was 
created through record linkages between the National Prostate Cancer Register (NPCR) of Sweden 
and nationwide health care registers and demographic databases and has been previously described 
11-12. Ethical permission was provided by the Research Ethics Board at Umeå University, Sweden.  
From both cohorts we identified men diagnosed between 2000 and 2010, with no evidence of 
metastatic disease (Mx or M0), aged <80 years and followed until death, emigration, or censorship 
(31st December 2015 for PCBaSe and 30th September 2013 for UK East of England), whichever 
occurred first. The median follow-up was 7.0 years (52% with 10 years or more follow up) in PCBaSe 
and 6.9 years (49% with 10 years or more follow up) in the UK East of England cohort. The outcome 
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died of other causes was excluded to remove the effect of other cause mortality for this comparison. 
Each man was assigned a CPG group with only those in CPG 1-3 studied further for this analysis. The 
webtool is available at  http://cambridgeprognosticgroup.com. Only subjects with all components of 
diagnostic stage, primary and secondary grade and presenting PSA (ng/ml) as well as data on follow 
up and survival were included as these variables were essential for the study. Any cases where these 
data were missing were not included. To investigate differences in PCM, we further sub-divided men 
in CPG2 and CPG3 by whether they were coded as being treated by primary radical therapy 
(prostatectomy or radiotherapy) or by the term conservative management. Men in CPG1 (similar to 
NICE and AUA defined low-risk) were used as the baseline comparator.  
 
Predicting progression and stratifying follow up on AS  
To explore factors that might predict the development of poorer prognosis disease we used a 
contemporary cohort of men on AS in our institution who had their disease burden optimally 
characterised by image-guided targeted and sectoral biopsies at the start of surveillance. The cohort, 
follow-up and outcomes have been previously described as was the institutional board approval 
(Cambridge University Hospital Trust, Cambridge, UK; registration number: 3592) [13]. Our standard 
diagnostic pathway was an initial 12-core sectoral transrectal prostate biopsy. A baseline mpMRI was 
performed at AS entry with the mpMRI used to then guide a subsequent early transperineal re-
biopsy performed using image-fusion software [13]. Where no lesion was identified, standard 
sectoral biopsies were performed. A reported lesion (of ≥3 on the Likert scale) was considered MRI 
positive. The only exceptions were men who had already had previous negative biopsies or those 
first diagnosed using a transperineal image-fusion method. This cohort thus had as accurate as 
possible characterisation of the actual disease burden at the start of AS to reduce/eliminate risks of 
misclassification and hence detect the true rates of disease progression. Briefly, included for this 
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a composite CPG criterion of 1 or 2 at entry, data on MRI prostate volume and derived PSA density 
and a minimum of 12 months follow up. All men had similar planned follow up with 3-monthly PSA 
testing, annual repeat mpMRI and scheduled protocol interval re-biopsies as previously reported 13. 
To re-test the finding we sourced an independent cohort from Spain (Valencia). This study was 
conducted under institutional review board approval (Ethics committee title: CAPROSIVO) and with a 
median follow-up of 2.9 years. This cohort included similar patients with the exception that Grade 
Group 2 was only allowed in men ≥ 70y and the PSA limit was up to 10 or PSAd < 0.20 if prostates 
were bigger than 60cc. As before a baseline mpMRI was performed at AS entry or before a repeat 
confirmatory biopsy if the diagnostic biopsy was a non-image guided 10-12 cores TRUS-guided 




The first analysis involved comparing the prostate cancer mortality (PCM) rate of men treated 
initially by radical therapy or conservative management and stratified by CPG criteria. The 10-year 
cumulative PCM rate was calculated for men in CPG2 and CPG3 and who were either treated or 
managed conservatively and compared with the PCM in for men in CPG1 (classical low-risk disease 
and used as the baseline comparator). The analysis was performed using lifetable command in 
STATA statistical package (STATA 15). In the second analysis, we explored predictors of progression 
to CPG3 in a contemporary AS cohort. For this analysis the variables considered included only data 
which would be available at baseline AS entry, namely CPG criteria, MRI lesion presence and PSA 
density (PSA divided by MRI defined tumour volume). To assess correlation between each predictor 
and progression to CPG3, we computed the Phi Correlation Coefficient, which is designed to 
measure the degree of relation for two variables which are binary. Comparisons of progression 
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(two-tailed) probability. Predictive test statistics were derived by calculating the true and false 
positive/negative rates. A multivariable model was not deemed statistically valid for this analysis 
given the relatively low number of events. A p value of <0.05 was used as a significance threshold.  
 
Results 
Comparison of 10-year cumulative PCM for men in CPG2 and CPG3 with versus without treatment 
The final UK cohort included 3659 men, of which 1299 were in CPG1, 1413 in CPG2 and 947 in CPG3 
cancer. Amongst men in CPG2, 477 were managed conservatively and 936 received radical therapy. 
The corresponding numbers in CPG3 were 179 and 768 respectively (Table S1). The 10-year 
cumulative PCM amongst men in CPG1 was 2.3%, consistent with the known excellent survival in 
men with low-risk disease 6. PCM in men with CPG2 was low whether managed by conservative 
management or radical treatment (3.5% versus 1.5%). The men who had treatment for a CPG3 
cancer had also a very low PCM of 1.9%. (Figure 1). In contrast, men in CPG3 who were managed 
conservatively had a nearly 4-fold higher PCM (8.3%) compared to untreated men and indeed to any 
other group. The final cohort from the PCBaSe database included 27,942 men with 15,477, 8495 and 
3970 men in CPG1, 2 and 3 respectively (Table S2). In this cohort the cumulative 10-year PCM was 
1.0% in CPG1, 2.7% in CPG2 untreated and 2.2% in CPG2 treated men. In contrast, untreated men 
with CPG3 had a 10-year PCM of 12.5%, twice as high as the mortality in CPG3 men who had initial 
radical therapy (6.1%) (Figure 2).  
Using CPG criteria to determine predictors of progression 
Our results suggest a clear advantage from radical therapy in men with CPG3, but only a minimal 
advantage for those with CPG1 or CPG2. This suggest that progression to CPG3 might be a valid 
criterion for switching to treatment. We asked if this criterion could be used to identify predictors of 
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3.5 years were used for this analysis. The attributes of the cohort and CPG assignments are shown in 
Table 2. A key advantage of this cohort for this analysis was the comprehensive up-front disease 
characterisation using image-guided re-biopsy allowing the assessment of the true rates of disease 
progression. In this cohort 22 men had evidence of progression during follow-up, but only 8 
progressed to CPG3 (6%). For predictors we focused on attributes available at the point of diagnosis. 
PSAd (cut-offs used were 0.10, 0.15 and 0.20 ng/ml/cm3), mpMRI positivity (Likert score of 3-5), CPG 
group at entry, biopsy core involvement and family history (first degree family member dying of 
prostate cancer) (Table 3). Correlation statistics showed that the key predictors of progression to 
CPG3 were a PSAd 0.15 (p=0.006), PSAd 0.20 (p<0.0001) and CPG2 disease at diagnosis (p=0.02). 
The presence of an MRI lesion itself was not overall a predictor of progression. To explore this 
further we stratified the cohort by mpMRI positivity. PSAd and CPG were equally predictive of 
progression whether or not there was an MRI lesion (Table S3). Men with an MRI positive lesion and 
a PSAd <0.15 however had a trend to a greater risk of progression (2/52, 3.8%) compared to men 
with a negative scan (0%) but this did not reach statistical significance.  
 
Stratified tiers of follow up based on progression risk  
These data were used to construct three surveillance follow-up tiers based on CPG and PSAd at 
diagnosis: Tier 1 CPG1 and PSAd<0.15, Tier 2 CPG2 OR PSAd0.15 and Tier 3 CPG2 AND PSAd0.15. 
Table 4A shows the percentage of men progressing in each tier along with the proportion of patients 
they represent in the UK cohort of 133 men. In brief 1%, 8% and 21% of men in Tiers 1,2 and 3 
progressed respectively (Negative Predictive Value of 99%). Men in the highest risk tier represented 
only 14% of the cohort whereas men in the lowest tier represented the majority (55%) of the cohort. 
We also modelled the use of these tiers if any pathological progression was used as the endpoint. 
Here the incidence of progression again showed a stepwise increase being lowest in men in tier 1 
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Spain of 143 men. The baseline characteristics of this cohort are shown in Table S5. In this cohort 23 
progressed but only 8/143 (5.5%) progressed to CPG3. Here the 3 tiers again identified different 
rates of progression to CPG3 with only 3% of men in Tier 1 progressing versus 14% of men in Tier 3 
(Negative Predictive Value of 97%) (Table 4B). Men in the highest tier represented only 5% of the 
cohort whereas men with the lowest risk (Tier 1) represented the majority of the cohort (68%). 
When any pathological progression was used as an endpoint, the model again showed utility with 
the incidence of progression being 10% in Tier 1 and 43% in Tier 3 (Table S4B).  
 
Discussion   
AS for early prostate cancer is an established management modality for early prostate cancer [2, 14-
15]. The use of MRI and image-guided biopsies has also increased confidence that high-grade 
cancers are less frequently missed at AS commencement and reduced the anxiety of surveying men 
[16-17]. With this increasing demographic, there is an imperative need to define which men are 
unsuitable for AS, rationalise follow-up and have well-evidenced hard stops. This has been 
notoriously difficult to achieve with a multitude of different guidelines, recommendations and no 
randomised trials [3, 18].  
An increasing body of evidence suggests that men with intermediate-risk disease may do very well 
from a non-interventional strategy [19-21]. Indeed, the current definition of intermediate-risk has 
been questioned with many cancers being designated Gleason sum 3+4 (Grade Group 2) instead of 6 
(following revisions to the ISUP grading system in 2005) without any material change in clinical 
outcomes [22-23]. Nevertheless, there remains controversy about AS as a strategy in men with 
intermediate-risk features. Data from the Toronto group suggest that men with Gleason sum 3+4 
(Grade Group 2) disease have a higher risk of metastasis compared to men with Gleason 3+3 disease 
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intermediate-risk disease had similar treatment conversion rates compared to men with low-risk 
disease [25]. The Canary Foundation PASS study also did not find significant association between 
baseline risk group and final radical prostatectomy pathology in men initially managed by AS [26].  
 
Our recent work has explored the innate heterogeneity within the traditional intermediate-risk 
classification and shown 2 distinct sub-groups with very different mortality and metastatic risks [8-9, 
27]. In this study we put this sub-classification to the test by comparing the PCM in men managed by 
either immediate radical therapy or conservative means. In a UK and a Swedish population cohort, 
together including over 31,000 men, we observed that a survival benefit from upfront radical 
treatment was evident only in men with CPG3 disease with an up to 4-fold reduction in PCM rates. 
These results are caveated by the fact that both populations were retrospective, non-randomised, 
did not strictly use AS (as it is currently known) and was inevitably likely subject to selection bias at 
initial treatment allocation. Nevertheless, the results mirror many other studies which have shown 
that unfavourable intermediate-risk disease (CPG3) is associated with a poorer outcome from AS 
compared to favourable intermediate-risk (CPG2) [25,28]. They are also consistent with results from 
the randomised ProtecT trial and other studies whereby the majority of men had low-risk or 
favourable intermediate-risk disease without survival differences between treated and untreated 
men [6,29]. While this paper was in preparation a multi-centre study from the US further showed 
that the distinction between favourable intermediate-risk (CPG2) and unfavourable intermediate-
risk disease (CPG3) also has utility in distinguishing men with different risks of metastasis after 
radical treatment [30]. Although AS was not explored in this study, it showed a starkly higher risk of 
metastasis at 10 years in men with CPG3 disease (10-13.5%) compared to CPG2 (0.2-3.5%) 
depending on the type of radical treatment. This study also, unsurprisingly, showed very different 
rates of prostate cancer mortality with results remarkably similar to our own findings [30]. Based on 
this, it would seem reasonable that progression to CPG3 is a pragmatic trigger to end AS and switch 
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materially affect prognosis. These data reinforce the fact that men with CPG3 should not be offered 
AS in the first place and also give reassurance that men with CPG2 disease can be safely offered 
surveillance. This could then help reduce variability and standardise National and International 
guidelines on AS as most do not use sub-divisions of intermediate-risk in their recommendations (3)  
Establishing a prognostically relevant trigger to end AS allows a pragmatic approach to defining risk 
factors for progression. To investigate this, we used two contemporary AS cohort that were 
optimally characterised at baseline with MRI-guided biopsies. A key attribute of the cohorts we have 
used here are the fact that early disease mis-classification was reduced as much as possible by early 
repeat image-guided biopsies. Short of removing the prostate for histological examination, it is as 
accurate as currently possible in determining correct risk assignment at the start of AS and hence 
allows a true measure of the rates of disease progression on AS especially in the short to medium 
term [31-32]. In these cohorts, progression to CPG3 occurred in only 6-8% of men over 3 years. The 
key predictors of progression were a high PSAd and CPG2 disease at the outset. It would be intuitive 
that starting with intermediate-risk disease confers a higher progression risk. Strikingly however, 
many men with CPG2 disease (32/37 in the UK series, >85%) actually did not progress. PSAd has 
been well reported to be a marker of progression in AS [33-35]. Remarkably the threshold value of 
0.15 has been found independently in many of these studies [33-35]. In our analysis the presence of 
a baseline MRI lesion was not predictive of progression and we had too few cases to sub-analyse 
differences between Likert 3, 4 and 5 lesions. We did observe that men with a low PSAd and a 
positive MRI had higher progression rates compared to those with a negative scan. MRI positivity 
may still be an important factor but our data was under-powered to identify it, alternatively, it might 
have specific value when the PSAd is low. Other studies have shown the value of adding mpMRI to 
guide repeat biopsies and improve grade reclassification though its role in monitoring remains 
keenly debated [32, 36-38]. Clearly though, using mpMRI as part of AS seems logical and a guide to 
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These insights allow us to propose a 3-tiered follow-up strategy applicable at the point of AS entry 
(Table 5). In this model the majority of men in AS (CPG1 and PSAd<0.15) could have long interval 
follow-ups. Conversely, the model also allows men at the top ends of inclusion (CPG2 and high PSAd) 
to also be monitored but with a closer regime. In our AS cohorts these men constituted only 5-14% 
of men. In comparison to a non-stratified approach our regime significantly reduces the need for 
out-patient review, imaging and biopsies for the majority of patients [3]. As an example, over 3 years 
our protocol would reduce out-patient visits alone by >50% compared to the current UK NICE 
guidelines [39]. Changes in the risk factors parameters during AS can also be used to revise the 
follow-up strategy as needed. For example, an increase to CPG2 or a higher PSAd may mean men are 
moved to a more intensive surveillance regime. Although baseline MRI itself was not overall 
correlated with progression to CPG3, it seems prudent that the presence of a lesion mandates a 
sooner repeat scan than in men with a negative scan (Table 5). Men should have at least 10 years 
Life Expectancy (LE) to be suitable for AS let alone be entered into this stratified model. We 
therefore propose that LE should be assessed at inclusion into the model, when a man is moved up 
to a higher tier or at the end of a 3 year cycle. Men with a LE of less than 10 years should be 
considered instead for watchful waiting with PSA and symptom monitoring only. 
 
There are limitations to this study and we consider our findings the basis for further testing and 
validation. Our prognostic outcomes were based on PCM as we were unable to model the impact on 
metastatic progression. However, it is unlikely that patients will progress undetected to metastasis 
on AS without first developing at least CPG3 disease. Indeed, we have previously shown that men in 
CPG1 and CPG2 never have de novo metastasis when identified using image-based diagnostics [27]. 
We did not compare the use of the CPG crterios to simply using Grade Groups alone in this study. 
Guidelines on risk-based management however never only use Grade as a criterion and always use a 
composite of PSA, Grade and Stage (AUA, NCCN, EAU, NICE). Moreover, we have previously seen in 










This article is protected by copyright. All rights reserved. 
similar outcomes to men with GG3 and low PSA [8-9]. For these reasons we feel that it is the 
composite score which is most relevant to clinical practice and AS management. Conservative 
management in our population datasets were not strictly AS cohorts as defined in the modern era as 
this term was not generally used in the early years nor was its definition standardised. However, if 
anything we would expect even better rates of survival in contemporary well characterised (though 
imaging and targeted biopsies) AS cohorts. Our studies did not find an association with biopsy core 
involvement which may be a true finding or a technical issue with how biopsies are reported. Of 
note, out of the 16 AS guideline protocols in a recent comprehensive review, only half mention core 
involvement and all used different thresholds [3]. MRI targeting has also changed the meaning of 
biopsy core information and it is currently unknown how this informs AS progression. Our cohorts 
were small and predominantly white European men but future work in multi-centre and multi-ethnic 
studies can also investigate the complimentary role of family history, race, testosterone levels and 
genetic factors in predicting progression [40]. Finally, all our cohort follow-ups were relatively short 
and extrapolation to longer term follow-up awaits future studies. However, all AS regimes involve 
iterative change depending on regular re-assessments. We similarly propose that our suggested 
follow-up forms the basis of a 3-year cycle at which point patients can be reclassified to CPG3 and 
end AS, moved on to a more stringent follow-up bracket or indeed remain in status quo. Finally, this 
model was built on the premise of using CPG3 or unfavourable intermediate-risk as endpoint but this 
may seem too risky for some clinicians to adopt. We did however also observe that the tiers did 
identify different risks of progression when any clinic-pathological progression was used as an 
endpoint. 
 
In summary, we present here a pragmatic approach to AS by using disease prognosis to guide 
inclusion, follow-up and surveillance discontinuation. Our data suggests that men with CPG2 
(favourable intermediate-risk disease) can be safely offered AS albeit with a closer follow up regime. 
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then there is little added survival benefit in conversion to active treatment if AS was selected as an 
initial management option. Important diagnostic predictors of progression are the baseline 
prognostic group and PSA density. Together with MRI positivity, these can be used to stratify follow-
up regimes with men with CPG1 (low risk disease) eligible for low intensity surveillance. Our results 
now need further testing in prospective multicentre trials to test their veracity in rationalising AS 
management without either compromising detection of significant progression or unnecessarily 
over-monitoring men.    
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Gleason score 6 (Grade Group 1) AND 




Gleason score 3 + 4 = 7 (Grade Group 2) 






Gleason score 3 + 4 = 7 (Grade Group 2) 
AND PSA 10–20 ng/ml AND Stage T1–T2 
OR 





One of Gleason score 8 (Grade Group 4) 






Any combination of Gleason score 8 
(Grade Group 4), PSA > 20 ng/ml or Stage 
T3 
OR 
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 Active Surveillance cohort n=133 
Median age (range) years 63 (46-76) 
Median prostate volume (range) mls 51 (20-148) 
Median PSA (range) ng/ml 6.4 (0.6-16.6) 
Median PSA density (range) ng/ml/cm3 0.12 (0.02-0.42) 
  
MRI positive (Likert 3-5) 73 
MRI negative  60 
  




Grade Group at AS entry  
Grade Group 1 (3+3) 122 
Grade Group 2 (3+4) 11 
  
Median follow up (range) months 39 (15-63) 
  
Active Surveillance status at last follow up  
Ongoing 110 
Pathological progression 16 
MRI progression 5 
PSA progression 1 
Died of other causes 1 
Progression to CPG3 8 
 
Table 2 – Cohort profile of the men on active surveillance from UK included in the analysis to assess 
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Table 3 – Analysis of correlation with baseline variables at diagnosis and progression to CPG3 (*1st 
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Criteria Numbers progressed 
(%) 
Cohort numbers                       
out of 133 men (%) 
CPG1  






CPG2                                         
OR                                               




CPG2                                         
AND                                              




                   A 
 
Criteria Numbers progressed 
(%) 
Cohort numbers                       
out of 143 men (%) 
CPG1  






CPG2                                         
OR                                               




CPG2                                         
AND                                              




                   B 
 
Table 4 A: Risks of progression to CPG3 in the UK cohort (n=133) using 3 categories defined by CPG 
score and PSA density (PSAd). These criteria identified 3 distinct groups with different rates of 
disease progression B: Applying the stratification in an external cohort from Valencia (Spain) (n=179) 
















Table 5 – Suggested integrated use of the CPG groups, PSA density (PSAd) and MRI positivity in 
structuring stratified follow up in AS using progression to CPG3 as the endpoint. The model assumes 
all men have optimal upfront diagnostics with image guided biopsies. The follow up can be reviewed 
at 3 years and repeated with patients continuing in the same or a higher surveillance group if 
needed. Use of biopsy core positivity and MRI lesion score can be used to adapt the strategy 
(Currently data on their impact on AS outcome and prognosis remains to be tested). * Life 
expectancy (LE) should be at least 10 years. If LE is <10 years then it is more appropriate for a 
watchful waiting strategy. LE should be assessed at inclusion, any progression or at the end of a 3 -
ear cycle to determine if ongoing AS/switch to treatment is appropriate or if the patient should 




Inclusion criteria Suggested follow up 
 
1  
Low           
Intensity 
 
CPG1                                         
PSAd<0.15 
LE 10 years* 
 
3-6 monthly PSA                                                         
18 monthly out-patients                                        
MRI at 3 years (no lesion) 
MRI at 18 months (lesion seen) 
No routine re-biopsy                                                  






CPG2                                         
OR                                              
PSAd  0.15 
LE 10 years 
 
3-6 monthly PSA                                                         
12 monthly out-patients                                        
MRI at 18 months (no lesion) 
MRI at 12 months (lesion seen) 
Re-biopsy at 3 years                                     
Triggered re-biopsy if any change 
 
3 
High            
Intensity 
 
CPG2                                         
AND                                              
PSAd  0.15 
LE 10 years 
 
3-6 monthly PSA                                                            
6 monthly out-patients                                        
MRI at 12 months                                                     
Re-biopsy at 2 years                                             




























Figure 1 – Cumulative probability of Prostate Cancer Mortality at 10 years for men in each of Cambridge Prognostic Group (CPG) 2 and 3 and whether they 
were managed conservatively (CM) or by radical therapy (Tx) in the UK cohort (n=3659). Comparison is made with outcomes in men with CPG1 (low-risk) 
disease. 
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Figure 2 – Cumulative probability of Prostate Cancer Mortality at 10 years for men in each of Cambridge Prognostic Group (CPG) 2 and 3 and whether they 
were managed conservatively (CM) or by radical therapy (Tx) in the Swedish PCBase cohort (n=27,942). Comparison is made with outcomes in men with 
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